A pivotal phase IIb/III trial of WT1 vaccine in patients with malignant pleural mesothelioma

Trial Profile

A pivotal phase IIb/III trial of WT1 vaccine in patients with malignant pleural mesothelioma

Planning
Phase of Trial: Phase II/III

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Galinpepimut S (Primary)
  • Indications Mesothelioma
  • Focus Registrational; Therapeutic Use
  • Sponsors Sellas Life Sciences Group
  • Most Recent Events

    • 14 Sep 2016 According to Sellas Life Sciences Group media release, this trial is expected to start in early 2017.
    • 14 Sep 2016 Planned initiation date changed from 1 Jul 2016 to 1 Jan 2017, as per Sellas Life Sciences Group media release.
    • 29 Mar 2016 According to SELLAS Life Sciences media release, based on results of phase II trial (see CTP 700192768), the company plans to initiate this pivotal trial of WT1 peptide vaccine in patients with MPM, in the third quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top